Jax DiEugenio

Since paraneoplastic neurologic syndromes remain underrecognized in oncology, experts recently discussed diagnostic challenges, treatment strategies, and the need for clinical vigilance.

Neuro-oncology experts examined how emerging cancer therapies may reshape the spectrum of paraneoplastic neurologic syndromes. [WATCH TIME: 4 minutes]

Neuro-oncology experts discussed best practices for initiating immunomodulatory therapy in patients with PNS, factors influencing neurologic recovery, and the role of early specialty involvement and supportive care in optimizing long-term outcomes. [WATCH TIME: 4 minutes]

Neuro-oncology experts examined how cumulative neurotoxicity from cytotoxic and targeted therapies can obscure paraneoplastic neurologic syndromes, and how treatment timing and modification decisions influence neurologic outcomes. [WATCH TIME: 6 minutes]

Neuro-oncology experts discussed how to differentiate classic PNS from immune-related neurologic adverse events, including the impact of prior immunotherapy exposure and the challenge of balancing neurologic stabilization with ongoing cancer treatment. [WATCH TIME: 5 minutes]

Neuro-oncology experts outlined screening strategies, antibody testing, and patient factors that help distinguish paraneoplastic neurologic syndromes from treatment toxicity and immune-related events. [WATCH TIME: 6 minutes]

A duo of neuro-oncologists from Northwestern Medicine discussed how paraneoplastic neurologic syndromes differ from other cancer-related neurologic complications, highlighting key diagnostic challenges.

A duo of neuro-oncologists from Northwestern Medicine explained how to distinguish paraneoplastic neurologic syndromes from treatment toxicity and metastatic disease. [WATCH TIME: 8 minutes]